Impax Labs Company Profile
What is the competitive landscape for IMPAX LABS
IMPAX LABS has one hundred and thirty-nine approved drugs.
There are three tentative approvals on IMPAX LABS drugs.
Summary for Impax Labs
| US Patents: | 0 |
| Tradenames: | 107 |
| Ingredients: | 107 |
| NDAs: | 139 |
Drugs and US Patents for Impax Labs
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Impax Labs | CARBIDOPA AND LEVODOPA | carbidopa; levodopa | TABLET, EXTENDED RELEASE;ORAL | 076521-002 | May 14, 2004 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Impax Labs | DIPYRIDAMOLE | dipyridamole | TABLET;ORAL | 040782-001 | Jul 18, 2007 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Impax Labs | MINOCYCLINE HYDROCHLORIDE | minocycline hydrochloride | CAPSULE;ORAL | 065005-003 | Apr 18, 2001 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for IMPAX LABS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
